46
Participants
Start Date
May 30, 2021
Primary Completion Date
February 5, 2024
Study Completion Date
August 13, 2025
APG2575 400 mg
APG2575 400 mg
APG2575 600 mg
APG2575 600 mg
APG2575 800 mg
APG2575 800 mg
St. Vincent Hospital, Melbourne
Weill Cornell Univ Hospitals, New York
Mayo Clinic, Jacksonville
MD Anderson, Houston
Colorado Blood Cancer Institute, Denver
City of Hope, Duarte
Nanfang Hospital, Guangzhou
Zhongshan Hospital of Fudan University, Shanghai
Beijing Chaoyang Hospital, Beijing
The First Affiliated Hospital,College Of Medicine,Zhejiang University, Hangzhou
The First Affiliated Hospital with Nanjing Medical University, Nanjing
The First Affiliated Hospital Of Soochow University, Suzhou
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin
Henan Cancer Hospital, Zhengzhou
Lead Sponsor
Ascentage Pharma Group Inc.
INDUSTRY